Active Ingredient History
Ranolazine is a metabolic modulator developed by Syntex (Roche) and sold under the trade name Ranexa by Gilead Sciences. Ranexa has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure. The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia. Because Ranexa prolongs the QT interval, it should be reserved for patients who have not achieved an adequate response with other antianginal drugs. Ranexa should be used in combination with amlodipine, beta-blockers or nitrates. The effect on angina rate or exercise tolerance appeared to be smaller in women than men. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Coronary Syndrome (Phase 2)
Amyotrophic Lateral Sclerosis (Phase 2)
Angina Pectoris (Phase 4)
Angina, Stable (Phase 4)
Arrhythmias, Cardiac (Phase 3)
Arteriosclerosis (Phase 4)
Atherosclerosis (Phase 2)
Atrial Fibrillation (Phase 4)
Cardiomyopathies (Phase 4)
Cardiomyopathy, Dilated (Phase 2)
Cardiomyopathy, Hypertrophic (Phase 4)
Cardiovascular Diseases (Phase 4)
Chest Pain (Phase 4)
Coronary Artery Disease (Phase 4)
Crohn Disease (Phase 2)
Death, Sudden, Cardiac (Phase 3)
Diabetes Mellitus, Type 1 (Phase 3)
Diabetes Mellitus, Type 2 (Phase 4)
Dyspnea (Phase 4)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 3)
Heart Failure, Diastolic (Phase 4)
Hypertension, Pulmonary (Phase 4)
Inflammatory Bowel Diseases (Phase 2)
Irritable Bowel Syndrome (Phase 2/Phase 3)
Kidney Diseases (Phase 1)
Kidney Failure, Chronic (Phase 4)
Long QT Syndrome (Phase 2)
Metabolic Syndrome (Phase 4)
Microvascular Angina (Phase 4)
Mitral Valve (Phase 4)
Myocardial Ischemia (Phase 4)
Myocardial Perfusion Imaging (Phase 4)
Myocardial Stunning (Phase 4)
Myotonia Congenita (Phase 2)
Myotonic Disorders (Phase 2)
Myotonic Dystrophy (Phase 2)
Nocturia (Phase 1)
Pain (Phase 4)
Peripheral Arterial Disease (Phase 4)
Peripheral Nervous System Diseases (Phase 4)
Pharmacology (Phase 1)
Polyneuropathies (Phase 4)
Polyuria (Phase 2)
Postoperative Complications (Phase 3)
Pulmonary Arterial Hypertension (Phase 3)
Recurrence (Phase 2/Phase 3)
Romano-Ward Syndrome (Phase 2)
Tachycardia, Ventricular (Phase 4)
Ventricular Premature Complexes (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
